Massimo Cristofanilli, MD
Hematology & Oncology · New York, NYNPI 1891880563
Payments from drug & device makers
Across 415 payments — averaging $5868.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$661K
- Pfizer$516K
- Merck$472K
- Menarini Silicon Biosystems, Inc.$358K
- Deciphera Pharmaceuticals Inc.$160K
- G1 Therapeutics, Inc.$92K
- plus $177K from 16 others
Across 27 payments — averaging $1515.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$38K
- Eli Lilly$3K
What the payments were for
- Consulting fees$193,08170%
- Speaking & faculty fees$52,44019%
- Travel & lodging$21,1558%
- Food & beverage$7,5593%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $660,543 |
| Pfizer(2 entities) | 53 | $515,784 |
| Merck | 51 | $472,403 |
| Menarini Silicon Biosystems, Inc. | 31 | $357,640 |
| Deciphera Pharmaceuticals Inc. | 93 | $160,390 |
| G1 Therapeutics, Inc. | 9 | $91,788 |
| Incyte Corporation | 65 | $66,428 |
| Astrazeneca UK Limited | 27 | $54,929 |
| Astrazeneca AB | 8 | $15,125 |
| Eli Lilly | 30 | $13,152 |
| Foundation Medicine, Inc. | 4 | $13,000 |
| Lilly USA, LLC | 5 | $4,398 |
| Dompe US, Inc. | 2 | $2,184 |
| Stemline Therapeutics Inc. | 2 | $1,998 |
| Puma Biotechnology, Inc. | 1 | $1,920 |
| Novartis | 4 | $1,883 |
| Gilead | 3 | $1,518 |
| Seagen Inc. | 1 | $105 |
| Pfizer Corporation Hong Kong Limited | 1 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$72,733
- KEYTRUDA$29,300
- CELLSEARCH$23,366
- FOUNDATIONFOCUS$13,000
- FOUNDATIONONE CDX$13,000
- FOUNDATIONONE HEME$13,000
- FOUNDATIONONE$13,000
- FOUNDATIONONE LIQUID$9,000
- LORBRENA$8,867
- Truqap$6,173
- Deparray$4,752
- FOUNDATIONACT$4,000
- VERZENIO$3,777
- Reparixin$2,100
- Orserdu$1,950
- Nerlynx$1,920
- BYL719$1,687
- Trodelvy$1,450
- KISQALI$167
How this compares
$2,435,315 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 12 | $139 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
- Joshua SabariNew York$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.